Shopping Cart 0
Cart Subtotal
USD 0

Dexcel PT Israel Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Dexcel PT Israel Ltd (Dexcel Pharma), a subsidiary of Dexcel PT Holdings Ltd, develops, manufactures and markets branded and generic pharmaceuticals. Its featured products include PerioChip (chlorhexidine gluconate), a non-antibiotic adjunct treatment for scaling and root planing and adult periodontitis; Deximune, an immunosppressant; and omeprazole delayed released tablet. The company's other products include cetirizine, diclofenac, losartan, metoprolol tartrate, and nicorandil. Dexcel Pharma develops formulations using proprietary, patent-protected, drug delivery technologies. It offers products for allergy, analgesics, cardiovascular, dental, dermatology and pain relief, among others. The company sells its products in the US, the UK and Germany, among other countries. Dexcel Pharma is headquartered in Or Akiva, Haifa, Israel.

Dexcel PT Israel Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Kitov Pharma Enters into Development Agreement with Dexcel 10

BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 11

Licensing Agreements 12

Dexcel Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 12

ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 13

Equity Offering 14

Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 14

Dexcel PT Israel Ltd-Key Competitors 16

Dexcel PT Israel Ltd-Key Employees 17

Dexcel PT Israel Ltd-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Appendix 19

Methodology 19

About GlobalData 19

Contact Us 19

Disclaimer 19


List Of Figure

List of Figures

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Dexcel PT Israel Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Kitov Pharma Enters into Development Agreement with Dexcel 10

BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 11

Dexcel Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 12

ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 13

Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 14

Dexcel PT Israel Ltd, Key Competitors 16

Dexcel PT Israel Ltd, Key Employees 17

Dexcel PT Israel Ltd, Other Locations 18

Dexcel PT Israel Ltd, Subsidiaries 18

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Dexcel PT Israel Ltd (Dexcel Pharma), a subsidiary of Dexcel PT Holdings Ltd, develops, manufactures and markets branded and generic pharmaceuticals. Its featured products include PerioChip (chlorhexidine gluconate), a non-antibiotic adjunct treatment for scaling and root planing and adult periodontitis; Deximune, an immunosppressant; and omeprazole delayed released tablet. The company's other products include cetirizine, diclofenac, losartan, metoprolol tartrate, and nicorandil. Dexcel Pharma develops formulations using proprietary, patent-protected, drug delivery technologies. It offers products for allergy, analgesics, cardiovascular, dental, dermatology and pain relief, among others. The company sells its products in the US, the UK and Germany, among other countries. Dexcel Pharma is headquartered in Or Akiva, Haifa, Israel.

Dexcel PT Israel Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Kitov Pharma Enters into Development Agreement with Dexcel 10

BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 11

Licensing Agreements 12

Dexcel Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 12

ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 13

Equity Offering 14

Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 14

Dexcel PT Israel Ltd-Key Competitors 16

Dexcel PT Israel Ltd-Key Employees 17

Dexcel PT Israel Ltd-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Appendix 19

Methodology 19

About GlobalData 19

Contact Us 19

Disclaimer 19


List Of Figure

List of Figures

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Dexcel PT Israel Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Kitov Pharma Enters into Development Agreement with Dexcel 10

BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 11

Dexcel Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 12

ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 13

Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 14

Dexcel PT Israel Ltd, Key Competitors 16

Dexcel PT Israel Ltd, Key Employees 17

Dexcel PT Israel Ltd, Other Locations 18

Dexcel PT Israel Ltd, Subsidiaries 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS